Proactiveinvestors United Kingdom Feedback PLC https://www.proactiveinvestors.co.uk Proactiveinvestors United Kingdom Feedback PLC RSS feed en Tue, 23 Jul 2019 13:16:07 +0100 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) <![CDATA[Media files - Feedback PLC's Cadran product 'the future of medical communication' - CEO ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/14064/feedback-plc-s-cadran-product--the-future-of-medical-communication----ceo-14064.html Thu, 11 Jul 2019 13:13:00 +0100 https://www.proactiveinvestors.co.uk/companies/stocktube/14064/feedback-plc-s-cadran-product--the-future-of-medical-communication----ceo-14064.html <![CDATA[News - Feedback chief says co will 'prioritise' Cadran product as focuses on secure messaging between doctors ]]> https://www.proactiveinvestors.co.uk/companies/news/223653/feedback-chief-says-co-will--prioritise--cadran-product-as-focuses-on-secure-messaging-between-doctors-223653.html Feedback PLC (LON:FDBK) said it is prioritising its Cadran picture archiving system ahead of its TexRAD technology for uncovering biomarkers in medical images.

The change of tack follows a strategic review by new chief executive Tom Oakley, who believes Cadran can become the go-to method of securely sharing patient information by mobile phone or tablet.

Research presented in the British Medical Journal reveals that 97% of doctors discuss patients via WhatsApp, which presents security and GDPR compliance issues.

Cadran not only provides an ultra-secure method of sharing information, it is the only communication tool to be CE marked as a medical device, Feedback pointed out. This means it has been through a rigorous EU approval process.

CEO Oakley said: "An exciting opportunity has arisen from the first phase of our strategic review.

“We believe that Cadran's innovative features, such as the ability to view clinical grade medical images flexibly on mobile and personal devices, allow it to be repositioned to meet the needs of an emerging medical communications market, particularly in medical imaging.

"There is huge potential to improve the efficiencies and lives of our doctors and patients alike, through more flexible, secure and accurate tools utilising the highest standards in global mobile communications. We are now working swiftly to develop this new offering and make it available for the many clinicians eager to use it, both within the NHS and internationally."

In the same announcement, the specialist medical imaging group said revenues for the year ended May were £563,000, up 23%.

]]>
Wed, 10 Jul 2019 07:59:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/223653/feedback-chief-says-co-will--prioritise--cadran-product-as-focuses-on-secure-messaging-between-doctors-223653.html
<![CDATA[RNS press release - Outcome of strategic review and trading update ]]> https://www.proactiveinvestors.co.uk/companies/rns/353/LSE20190710070003_14142593/ Wed, 10 Jul 2019 07:00:03 +0100 https://www.proactiveinvestors.co.uk/companies/rns/353/LSE20190710070003_14142593/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/353/LSE20190610092851_14104604/ Mon, 10 Jun 2019 09:28:51 +0100 https://www.proactiveinvestors.co.uk/companies/rns/353/LSE20190610092851_14104604/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/353/LSE20190607100758_14103077/ Fri, 07 Jun 2019 10:07:58 +0100 https://www.proactiveinvestors.co.uk/companies/rns/353/LSE20190607100758_14103077/ <![CDATA[Media files - Proactive meets new Feedback CEO as strategic review progresses ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/13132/proactive-meets-new-feedback-ceo-as-strategic-review-progresses-13132.html Mon, 29 Apr 2019 15:42:00 +0100 https://www.proactiveinvestors.co.uk/companies/stocktube/13132/proactive-meets-new-feedback-ceo-as-strategic-review-progresses-13132.html <![CDATA[News - Feedback expecting significant revenue growth ]]> https://www.proactiveinvestors.co.uk/companies/news/219068/feedback-expecting-significant-revenue-growth-219068.html Feedback PLC (LON:FDBK), the specialist medical imaging technology company, is expecting to report significant revenue growth in the current financial year.

In a short trading update covering trading in the fiscal year to 31 May, the company said the recruitment of new personnel and the investment in product sales in the first half of the financial year had given the top-line the anticipated boost but the real benefit is expected to filter through in the years to come.

In the meantime, that same investment has increased the company's cost base; as a result, the loss for the current financial year will reflect such investment but not the total anticipated income.

The strategic review of the business kicked off earlier this month by the new chief executive officer of the company, Tom Oakley, is still in progress.


 

]]>
Thu, 25 Apr 2019 07:19:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/219068/feedback-expecting-significant-revenue-growth-219068.html
<![CDATA[RNS press release - Trading update ]]> https://www.proactiveinvestors.co.uk/companies/rns/353/LSE20190425070006_14050993/ Thu, 25 Apr 2019 07:00:06 +0100 https://www.proactiveinvestors.co.uk/companies/rns/353/LSE20190425070006_14050993/ <![CDATA[News - Feedback appoints subsidiary CEO as new chief executive ]]> https://www.proactiveinvestors.co.uk/companies/news/218207/feedback-appoints-subsidiary-ceo-as-new-chief-executive-218207.html Feedback PLC (LON:FDBK) has appointed the chief executive (CEO) of its operating subsidiary, Feedback Medical, as its own CEO with immediate effect.

Dr Tom Oakley, who became CEO of Feedback Medical in mid-February, is a qualified clinical radiologist who has previously served as director of NHS services at telemedicine firm Synergix Health, while he also founded Innovation Doctor, which explored the digital healthcare space.

READ:​ Feedback appoints Dr Tom Oakley as new chief executive of subsidiary

Feedback added that Dr Alastair Riddell, its current executive chairman, would resume the role of non-executive chairman which he occupied prior to June 2018.

Oakley said that he planned to complete a full review of the business “over the coming weeks” in order to “maximise Feedback's market position, identify growth areas and review new potential market areas within digital imaging”.

Feedback specialises in software used to analyse and manage medical imaging databases.

]]>
Tue, 09 Apr 2019 08:00:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/218207/feedback-appoints-subsidiary-ceo-as-new-chief-executive-218207.html
<![CDATA[RNS press release - Feedback Medical CEO appointed Feedback plc CEO ]]> https://www.proactiveinvestors.co.uk/companies/rns/353/LSE20190409070008_14033340/ Tue, 09 Apr 2019 07:00:08 +0100 https://www.proactiveinvestors.co.uk/companies/rns/353/LSE20190409070008_14033340/ <![CDATA[News - Feedback looks to ramp up marketing in 2019 as it appoints new CEO to trading subsidiary ]]> https://www.proactiveinvestors.co.uk/companies/news/215150/feedback-looks-to-ramp-up-marketing-in-2019-as-it-appoints-new-ceo-to-trading-subsidiary-215150.html What Feedback does

Feedback PLC (LON:FDBK), through its trading subsidiary Feedback Medical Limited, is a company specialising in medical imaging technology like magnetic resonance imaging (MRI) scans and X-Rays.

The company’s products, TexRAD and CADRAN, help radiologists, clinicians, and medical researchers improve their workflows as well as providing insights into diseases such as cancer.

The firm has its headquarters in Cambridge and operates internationally.

Feedback’s products

TexRAD

TexRAD is a patented software tool that helps identify biomarkers (naturally occurring characteristics in diseases or other biological manifestations) in medical images that are often invisible to the naked eye.

The technology has a particular significance in oncology, the medical field concerned with the treatment of cancer.

The technology’s first clinical application is TexRAD Lung, which can help reveal information on lung tumours, whereas the other application, TexRAD Research, is used to compliment existing infrastructure to help analyse medical image scans.

CADRAN

CADRAN is a system that helps users store, manage, and view medical images. It helps doctors access images for diagnosis, treatment planning, and response measurement as well as facilitating knowledge sharing between multi-disciplinary teams.

The CADRAN range consists of four products;

• CADRAN PACS – The Picture Archiving and Communication System (PACS) provides mid-scale departments with a network server, image viewer, and web interface to access images

• Mini PACS – A small-scale system for image storage and management using dedicated servers and workstations. Designed for smaller imaging clinics and remote workers

• Viewer+ - Displays medical images from imaging equipment using a standard desktop PC or laptop with measurement and analysis tools. Designed for convenience use and individuals

• CADRAN Web – allows remote access to images through a web-accessible image library. Can be viewed on desktop PC or laptop

Inflexion points

• In February, the firm appointed Dr Tom Oakley, a qualified radiologist and former director of NHS services at telemedicine firm Synergix Health, as the new chief executive of Feedback Medical

• The company signed an agreement in Janaury with software development partner Future Processing to enhance their software development capability as well as distribute relevant Future Processing imaging analysis products, which according to Feedback chairman Alastair Riddell would earn the firm a “very healthy double-digit commission''

• In the first half of its fiscal year, Feedback saw a sharp increase in invoiced sales, which jumped 22% to £271,000 in the six months to 30 November 2018

Blue Sky

Speaking to Proactive in January, Riddell said that going forward the firm was keen to ramp up the sales and marketing for CADRAN, which is its higher margin product.

“We have a very high quality company and high quality products, and importantly we have an installed base of 60 very prestigious institutions around the world. We are now ready to invest in our products to grow market share”.

Commenting on the appointing of the new CEO Tom Oakley, Riddell said that the new exec’s “proven track record in leading and developing innovative medical products, and his deep understanding of the NHS will be essential in driving growth for both TexRAD and Cadran”.

The group is also in ongoing discussions with various medical imaging software companies and service providers to partner with and integrate its TexRAD Lung product within their platforms and potentially sell the software globally.

With shares trading at around 1.3p as of 21 February, Feedback carries a market cap of £4.76mln.

]]>
Fri, 22 Feb 2019 09:00:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/215150/feedback-looks-to-ramp-up-marketing-in-2019-as-it-appoints-new-ceo-to-trading-subsidiary-215150.html
<![CDATA[News - Feedback appoints Dr Tom Oakley as new chief executive of subsidiary ]]> https://www.proactiveinvestors.co.uk/companies/news/214612/feedback-appoints-dr-tom-oakley-as-new-chief-executive-of-subsidiary-214612.html Medical imaging specialist Feedback PLC (LON:FDBK) has appointed Dr Tom Oakley as the chief executive of its Feedback Medical subsidiary.

Oakley is a qualified clinical radiologist and has “significant experience” of launching healthcare products and helping small companies to realise and grow their market potential, Feedback said.

He has served as director of NHS services at telemedicine firm Synergix Health, while he also founded Innovation Doctor, which explored the digital healthcare space.

READ: Feedback seeing ‘continued progress’

“I am joining Feedback Medical at a key time for the company,” said Oakley.

“It has great potential in a market poised for strong growth, with its innovative TexRAD and Cadran products. I am keen to help the company consolidate its market position, identify growth areas and capture the emerging market segment within digital imaging.”

Executive chairman, Alastair Riddell, added: “Tom's proven track record in leading and developing innovative medical products, and his deep understanding of the NHS will be essential in driving growth for both TexRAD and Cadran.

“His combination of clinical knowledge and understanding of market access will be valuable as Feedback Medical grows towards its potential as a leader within the digital imaging sector.”

TexRAD the focus

Feedback is developing TexRAD – a very smart piece of software that analyses medical images to reveal features that are not always evident to the human eye.

The company is already making money from TexRAD with sales to institutions carrying out research, but the promised land is filled with sales to hospitals.

Back in September, it received an order from the Samsung Medical Centre in Seoul, while it has since made several sales in Europe.

]]>
Thu, 14 Feb 2019 07:32:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/214612/feedback-appoints-dr-tom-oakley-as-new-chief-executive-of-subsidiary-214612.html
<![CDATA[RNS press release - Feedback Medical appoints Dr Tom Oakley as CEO ]]> https://www.proactiveinvestors.co.uk/companies/rns/353/LSE20190214070012_13968821/ Thu, 14 Feb 2019 07:00:12 +0000 https://www.proactiveinvestors.co.uk/companies/rns/353/LSE20190214070012_13968821/ <![CDATA[Media files - Feedback PLC's Alastair Riddell outlines substantial deal with Future Processing ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/12037/feedback-plc-s-alastair-riddell-outlines-substantial-deal-with-future-processing-12037.html Wed, 30 Jan 2019 15:11:00 +0000 https://www.proactiveinvestors.co.uk/companies/stocktube/12037/feedback-plc-s-alastair-riddell-outlines-substantial-deal-with-future-processing-12037.html <![CDATA[News - Feedback sees "continued positive progress" ]]> https://www.proactiveinvestors.co.uk/companies/news/213225/feedback-sees--continued-positive-progress--213225.html Specialist medical imaging technology company Feedback PLC (LON:FDBK) saw a sharp increase in invoiced sales in the first half of its fiscal year.

Invoiced sales for the six months to 30 November rose 22% from a year earlier to £271,000 (2017: £222,000).

READ: Feedback delivers robust growth in invoiced sales in year of "transition and growth'

Recognised revenue for the period rose 4% to £236,000 from £229,000 the year before. The difference between sales and revenue is due to the contract structures, which typically comprise installation costs, a contract for a year or more, followed by a 20% annual maintenance fee thereafter.

Primarily as a result of the higher cost base following the recruitment programme in 2018 and increased investment in software development, the loss before tax widened to £407,000 from £352,000 in the first half of the year before.

Investment in software development during the period was ramped up to £106,000 from £41,000 the year before.

The company ended the period with £1.37mln cash, up from £267,000 at the end of November 2017, following the company’s fundraising in October.

 

Feedback said international interest in its TexRAD quantitative analysis platform had continued throughout the first half of the fiscal year.

READ: Feedback surges on potential collaboration with Alliance Medical

Commercial and technical discussions continue with Alliance Medical. Feedback is also in active discussions with other medical imaging software companies and service providers to partner with and integrate TexRAD Lung within their platforms and potentially sell within the UK and beyond.

As for Cadran, Feedback’s picture archiving and communication system, the company is focusing on its image archiving, retrieval, storage and anonymisation capabilities with several eminent clinical centres.

"We have seen positive progress across the business during this six-month period, building European sales as well as global sales in the US, South Korea and India,” said Dr Alastair Riddell, the executive chairman of Feedback.

“We have recruited to provide an additional resource in data science and to support Cadran and this month, we have strengthened our partnership with Future Processing. This will bring increased software development capabilities and improved functionality to our technology as well as access to specialist medical imaging and AI expertise,” he added.

]]>
Thu, 24 Jan 2019 07:26:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/213225/feedback-sees--continued-positive-progress--213225.html
<![CDATA[RNS press release - Half-year Results ]]> https://www.proactiveinvestors.co.uk/companies/rns/353/LSE20190124070004_13944811/ Thu, 24 Jan 2019 07:00:04 +0000 https://www.proactiveinvestors.co.uk/companies/rns/353/LSE20190124070004_13944811/ <![CDATA[RNS press release - Result of AGM ]]> https://www.proactiveinvestors.co.uk/companies/rns/353/LSE20190123140229_13944484/ Wed, 23 Jan 2019 14:02:29 +0000 https://www.proactiveinvestors.co.uk/companies/rns/353/LSE20190123140229_13944484/ <![CDATA[Media files - Feedback Plc welcomes first institutional investor as sales momentum builds ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/11488/feedback-plc-welcomes-first-institutional-investor-as-sales-momentum-builds-11488.html Thu, 06 Dec 2018 12:18:00 +0000 https://www.proactiveinvestors.co.uk/companies/stocktube/11488/feedback-plc-welcomes-first-institutional-investor-as-sales-momentum-builds-11488.html <![CDATA[RNS press release - Total Voting Rights ]]> https://www.proactiveinvestors.co.uk/companies/rns/353/LSE20181130170002_13887723/ Fri, 30 Nov 2018 17:00:02 +0000 https://www.proactiveinvestors.co.uk/companies/rns/353/LSE20181130170002_13887723/ <![CDATA[News - Feedback delivers robust growth in invoiced sales in year of "transition and growth' ]]> https://www.proactiveinvestors.co.uk/companies/news/210240/feedback-delivers-robust-growth-in-invoiced-sales-in-year-of-transition-and-growth--210240.html Medical imaging technology company Feedback PLC (LON:FDBK) said the last year has been a “period of transition and major growth” for the business as it reported a 51% increase in invoiced sales.

In the year to May 31, invoiced sales rose to £771,000 from £508,000 a year ago after the firm invested in training and recruiting staff and won a two-year contract renewal with Royal Papworth Hospital NHS Foundation Trust for its Cadran picture archiving communication system (PACS), which provides decision support for scan analysis.

The company also secured a software licence and distribution agreement for its TexRAD patented image texture analysis technology with General Electric Healthcare (GEHC), a subsidiary of US conglomerate General Electric (NYSE:GE), in the period. The first order through GE Healthcare was received in August.

WATCH: Feedback Plc welcomes first institutional investor as sales momentum builds

In September Feedback received an order for TexRAD from Samsung Medical Centre under a distribution agreement made with ISG Korea in June 2017.

A month later it received a number of new significant orders for TexRAD from prestigious university hospitals across Europe, including in Belgium and Portugal.

Restructuring yields benefits for Feedback 

The 2018 financial year saw Feedback undergo a restructuring to bring its TexRAD Ltd and Cambridge Computed Imaging (CCI) subsidiaries together under Feedback Medical brand. Restructuring and recruitment costs led to a wider operating loss of £750,000 for the year, compared to £300,000 last year.

Chief executive Alastair Riddell said:  “The board has been strengthened and the restructuring of our operating subsidiaries into one integrated unit under the Feedback Medical brand is already bringing benefits, demonstrated by the significant improvement in sales performance.”

“During the year and post period end, we secured significant investment from new and existing shareholders, enabling us to invest further in the sales and marketing of both TexRAD and Cadran, including pursuing US FDA approval.”

Solid 2019 first-quarter sales 

Feedback said increased sales momentum was seen particularly towards the end of the year and this has continued into the new financial year with significant traction from Asian markets.

In the first quarter, invoiced sales of TexRAD and Cadran products surged 100% to £236,000, compared to £117,000 the same period a year ago.

READ: Feedback reports 100% jump in first-quarter sales as international business soars

The group sees additional sales growth potential in the “mid to long-term” with its first clinical product approved the European Union and pilot launches underway.

]]>
Thu, 29 Nov 2018 15:16:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/210240/feedback-delivers-robust-growth-in-invoiced-sales-in-year-of-transition-and-growth--210240.html
<![CDATA[RNS press release - Final Results ]]> https://www.proactiveinvestors.co.uk/companies/rns/353/LSE20181129143736_13885690/ Thu, 29 Nov 2018 14:37:36 +0000 https://www.proactiveinvestors.co.uk/companies/rns/353/LSE20181129143736_13885690/ <![CDATA[RNS press release - Feedback retains industry standard certification ]]> https://www.proactiveinvestors.co.uk/companies/rns/353/LSE20181122125947_13877403/ Thu, 22 Nov 2018 12:59:47 +0000 https://www.proactiveinvestors.co.uk/companies/rns/353/LSE20181122125947_13877403/ <![CDATA[RNS press release - Director/PDMR Shareholding ]]> https://www.proactiveinvestors.co.uk/companies/rns/353/LSE20181119145648_13872313/ Mon, 19 Nov 2018 14:56:48 +0000 https://www.proactiveinvestors.co.uk/companies/rns/353/LSE20181119145648_13872313/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/353/LSE20181119114935_13872022/ Mon, 19 Nov 2018 11:49:35 +0000 https://www.proactiveinvestors.co.uk/companies/rns/353/LSE20181119114935_13872022/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/353/LSE20181116091635_13869946/ Fri, 16 Nov 2018 09:16:35 +0000 https://www.proactiveinvestors.co.uk/companies/rns/353/LSE20181116091635_13869946/ <![CDATA[RNS press release - Result of General Meeting ]]> https://www.proactiveinvestors.co.uk/companies/rns/353/LSE20181115113558_13868588/ Thu, 15 Nov 2018 11:35:58 +0000 https://www.proactiveinvestors.co.uk/companies/rns/353/LSE20181115113558_13868588/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/353/LSE20181101151138_13851989/ Thu, 01 Nov 2018 15:11:38 +0000 https://www.proactiveinvestors.co.uk/companies/rns/353/LSE20181101151138_13851989/ <![CDATA[RNS press release - Total Voting Rights ]]> https://www.proactiveinvestors.co.uk/companies/rns/353/LSE20181031170001_13850175/ Wed, 31 Oct 2018 17:00:01 +0000 https://www.proactiveinvestors.co.uk/companies/rns/353/LSE20181031170001_13850175/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/353/LSE20181031161506_13850101/ Wed, 31 Oct 2018 16:15:06 +0000 https://www.proactiveinvestors.co.uk/companies/rns/353/LSE20181031161506_13850101/ <![CDATA[RNS press release - Notice of General Meeting ]]> https://www.proactiveinvestors.co.uk/companies/rns/353/LSE20181029144440_13846362/ Mon, 29 Oct 2018 14:44:40 +0000 https://www.proactiveinvestors.co.uk/companies/rns/353/LSE20181029144440_13846362/ <![CDATA[Media files - Feedback plc's Alastair Riddell expands on £1.38mln fundraise and Europe deals ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/11004/feedback-plc-s-alastair-riddell-expands-on-138mln-fundraise-and-europe-deals-11004.html Fri, 26 Oct 2018 14:20:00 +0100 https://www.proactiveinvestors.co.uk/companies/stocktube/11004/feedback-plc-s-alastair-riddell-expands-on-138mln-fundraise-and-europe-deals-11004.html <![CDATA[News - Feedback directors buy shares as company raises funds ]]> https://www.proactiveinvestors.co.uk/companies/news/207828/feedback-directors-buy-shares-as-company-raises-funds-207828.html Following the news on Monday of several contract wins, Feedback PLC (LON:FDBK) has conditionally raised £1.38mln through the issue of shares at 1.5p each.

The specialist medical imaging technology company said £832,000, before expenses, has been raised via the placing while a further £543,000 will be raised by a subscription, assuming shareholders approve it.

READ: Feedback wins TexRAD orders from a slew of European university hospitals

Four Feedback directors have subscribed for 6.93mln shares at a cost of £104,000.

The newly issued shares will represent 24.56% of the enlarged issued share capital.

The funds will be used to expand the company’s sales and marketing services; develop technical product support for the new Cadran image storage product offerings and expand the Cadran customers base; fund regulatory consultant commission costs relating to the company’s plans to secure regulatory approval of TexRAD with the Food & Drug Administration (FDA) in the US; develop the company’s US partnership with Imaging Endpoints.

Our new website is now live!! ????????????
You can now find all the information you need about CADRAN and TexRAD in one website! https://t.co/aYRjHKXfI0 #TexRAD #CADRAN #FBKmed #Radiology #MedicalImaging #Radiomics #Oncology #textureanalysis #WednesdayMotivation

— Feedback Medical Ltd (@FBKmed) September 19, 2018

"This placing will enable Feedback to continue to invest in the further growth of the business. In particular, in the fields of image analysis with TexRAD, and AI applications in linking image data to anonymised patient data with Cadran. In addition, beginning the process of seeking US FDA approval for TexRAD can now be properly resourced. Expanding our sales, marketing and customer support capabilities, will ensure that we can build on the significant momentum generated this year," said Dr Alastair Riddell, the executive chairman of Feedback.

Shares in Feedback were down 0.15p at 1.55p in early deals.

]]>
Thu, 25 Oct 2018 08:39:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/207828/feedback-directors-buy-shares-as-company-raises-funds-207828.html
<![CDATA[RNS press release - Proposed placing and subscription to raise £1.375m ]]> https://www.proactiveinvestors.co.uk/companies/rns/353/LSE20181025070005_13841596/ Thu, 25 Oct 2018 07:00:05 +0100 https://www.proactiveinvestors.co.uk/companies/rns/353/LSE20181025070005_13841596/ <![CDATA[News - Feedback wins TexRAD orders from a slew of European university hospitals ]]> https://www.proactiveinvestors.co.uk/companies/news/207541/feedback-wins-texrad-orders-from-a-slew-of-european-university-hospitals-207541.html Feedback PLC (LON:FDBK), the specialist medical imaging technology company, has received a number of new significant orders for TexRAD technology.

The orders for its patented image texture analysis technology have been placed by prestigious university hospitals across Europe, including the first orders from universities in Belgium and Portugal.

READ: Feedback receives order for its TexRAD imaging technology for the Samsung Medical Centre in Seoul

Specifically, the TexRAD orders have come from Universitair Ziekenhuis Gent, Belgium; Beaujon Hospital, University Hospital Clichy, Service d'Imagerie médicale, France; ICNAS Producao Unip. Lda (Coimbra), Portugal; and University of Cagliari - Department of Diagnostic Imaging and Radiology, Italy.

The orders have arisen from an increase in business development activities during the year, Feedback said. These include scientific presentations and peer group referrals from previous purchasers of TexRAD.

Picture from the exhibition stand at The 34th Annual Meeting of the Korean Society for Radiation Oncology in Seoul, South Korea today! #TexRAD https://t.co/P67kvnkepP #Cancer #Oncology #Radiology #textureanalysis #Radiomics #TexRAD #FBKmed #FridayFeeling @balajiganeshan pic.twitter.com/phq8vjl2NV

— Feedback Medical Ltd (@FBKmed) October 12, 2018

"These recent orders of TexRAD are further validation of Feedback Medical and our technology,” said Dr Balaji Ganeshan, global business development director of Feedback Medical Lts.

“We are taking advantage of our growing reputation to drive new business. These new business wins have resulted from having referrals from current customers and penetrating new country markets. TexRAD is now being used in a diverse range of research fields which demonstrates the significant potential and applicability of our technology," he added.

Shares in Feedback were up 2.9% at 1.8525p.

 

]]>
Mon, 22 Oct 2018 08:30:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/207541/feedback-wins-texrad-orders-from-a-slew-of-european-university-hospitals-207541.html
<![CDATA[RNS press release - Expansion of European customer base ]]> https://www.proactiveinvestors.co.uk/companies/rns/353/LSE20181022070008_13836507/ Mon, 22 Oct 2018 07:00:08 +0100 https://www.proactiveinvestors.co.uk/companies/rns/353/LSE20181022070008_13836507/ <![CDATA[News - Feedback reports 100% jump in first quarter sales as international business soars ]]> https://www.proactiveinvestors.co.uk/companies/news/206266/feedback-reports-100-jump-in-first-quarter-sales-as-international-business-soars-206266.html Feedback PLC (LON:FDBK) has reported a 100% increase in its sales for the first quarter of the financial year, driven by a strong upswing in its international business.

In a trading update, the medical imaging specialist said first-quarter sales had risen to £236,000 from £117,000 a year ago, with international sales increasing over 200% in the same period.

WATCH: Feedback PLC hails TexRAD order from Samsung Medical Centre in Seoul

The company also updated on its sales for the last financial year, which rose 51% to £771,000 with recognised revenue in the year coming in at £458,000 compared to £466,000 previously.

The sales increase was boosted by investments in training and recruitment of additional staff, which had increased the company’s operating loss to £750,000 from £300,000 the year before.

In its outlook, Feedback said it was seeing “considerable sales growth potential” in the near to mid-term, particularly in the Asian market.

Last month, the firm received an order for its TexRAD image texture analysis technology from its South Korean distributor for the Samsung Medical Centre in Seoul, one of the country’s leading hospital groups.

The company also said it had initiated plans to obtain regulatory and marketing approval of TexRAD with the US Food and Drug Administration (FDA) as both a medical device and for use in clinical trials.

Feedback added that it was considering additional funding for its mid-term working capital requirements and planned to raise the funds through “public or private financings and/or partnering opportunities”.

Dr Alastair Riddell, executive chairman of Feedback, said: “As a result of the investment in our employees, we are seeing improved sales momentum throughout the business, demonstrated by the number and size of orders coming through and in the high calibre international distributors we are now working with."

]]>
Wed, 03 Oct 2018 08:02:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/206266/feedback-reports-100-jump-in-first-quarter-sales-as-international-business-soars-206266.html
<![CDATA[RNS press release - Trading update ]]> https://www.proactiveinvestors.co.uk/companies/rns/353/LSE20181003070004_13814026/ Wed, 03 Oct 2018 07:00:04 +0100 https://www.proactiveinvestors.co.uk/companies/rns/353/LSE20181003070004_13814026/ <![CDATA[RNS press release - Appointment of Joint Broker ]]> https://www.proactiveinvestors.co.uk/companies/rns/353/LSE20181001070006_13810164/ Mon, 01 Oct 2018 07:00:06 +0100 https://www.proactiveinvestors.co.uk/companies/rns/353/LSE20181001070006_13810164/ <![CDATA[Media files - Feedback PLC hails TexRAD order from Samsung Medical Centre in Seoul ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/10421/feedback-plc-hails-texrad-order-from-samsung-medical-centre-in-seoul-10421.html Mon, 10 Sep 2018 15:06:00 +0100 https://www.proactiveinvestors.co.uk/companies/stocktube/10421/feedback-plc-hails-texrad-order-from-samsung-medical-centre-in-seoul-10421.html <![CDATA[News - Feedback receives order for its TexRAD imaging technology for the Samsung Medical Centre in Seoul ]]> https://www.proactiveinvestors.co.uk/companies/news/204498/feedback-receives-order-for-its-texrad-imaging-technology-for-the-samsung-medical-centre-in-seoul-204498.html Feedback plc (LON:FDBK) has announced that its operating company Feedback Medical Ltd has received an order from its South Korean distributor for its patented image texture analysis technology, TexRAD for the Samsung Medical Centre in Seoul.

The specialist medical imaging technology company said the order came via its South Korean distributor, Korea Computer Motion ISG.

WATCH: TexRAD order 'just the first of many' Feedback are hoping to announce

It follows the exclusive distributor arrangement announced on 8 June 2017 granting Korea ISG the ability to sell and distribute TexRAD in South Korea for research purposes, performing advanced analysis of routinely acquired medical diagnostic images, such as CT and MRI scans.

To date, Korea ISG has obtained several orders for Feedback's TexRAD software technology in the country.

This is the first order from Samsung Medical Centre, one of the nation's leading hospital groups, founded by Samsung Group. Samsung Medical Centre has a strong focus on research, particularly in radiology and oncology.

Dr Balaji Ganeshan, Global Business Development Director of Feedback Medical Ltd, said: "The order of TexRAD by such a cutting-edge medical facility as the Samsung Medical Centre is a great validation of the capabilities of our technology platform.

“We are seeing increasing traction within our international distributor network as our reputation grows."

]]>
Mon, 10 Sep 2018 07:49:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/204498/feedback-receives-order-for-its-texrad-imaging-technology-for-the-samsung-medical-centre-in-seoul-204498.html
<![CDATA[RNS press release - TexRAD® ordered by Samsung Medical Centre in Seoul ]]> https://www.proactiveinvestors.co.uk/companies/rns/353/LSE20180910070007_13783874/ Mon, 10 Sep 2018 07:00:07 +0100 https://www.proactiveinvestors.co.uk/companies/rns/353/LSE20180910070007_13783874/ <![CDATA[RNS press release - Director/PDMR Shareholding ]]> https://www.proactiveinvestors.co.uk/companies/rns/353/LSE20180817140200_13760033/ Fri, 17 Aug 2018 14:02:00 +0100 https://www.proactiveinvestors.co.uk/companies/rns/353/LSE20180817140200_13760033/ <![CDATA[Media files - TexRAD order 'just the first of many' Feedback Plc are hoping to announce ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/10149/texrad-order-just-the-first-of-many-feedback-plc-are-hoping-to-announce-10149.html Thu, 16 Aug 2018 10:52:00 +0100 https://www.proactiveinvestors.co.uk/companies/stocktube/10149/texrad-order-just-the-first-of-many-feedback-plc-are-hoping-to-announce-10149.html <![CDATA[News - Feedback lands first contract from its tie-up with imaging giant GE Healthcare ]]> https://www.proactiveinvestors.co.uk/companies/news/202923/feedback-lands-first-contract-from-its-tie-up-with-imaging-giant-ge-healthcare-202923.html Shares in Feedback plc (LON:FDBK) shot up 17% on Wednesday on news it had received its first order from GE Healthcare for TexRAD, its image texture technology.

The contract is the first from a distribution agreement signed in April with the American diagnostics giant.

READ: Feedback’s new boss sets out his stall after strategic review

The end user will be the Post Graduate Institute of Medical Education & Research, Chandigarh, India. 

Feedback business development director, Dr Balaji Ganeshan, called the deal an “important milestone”.

“That one of India's leading medical institutions has selected TexRAD against other image analysis candidates is a strong endorsement of our technology," he added.

TexRAD was the brainchild of Ganeshan, an expert on textural analysis of images gleaned from computed tomography (CT) scans.

Smart piece of software

Distilled down to the basics, it is essentially a very smart piece of software that analyses medical images to reveal features that are not always evident to the human eye.

In doing so, it may “in a very statistical, objective and numerical way relate the output to a prognosis for the patient”, chairman Dr Alastair Riddell told Proactive recently.

Feedback is already making money from TexRAD with sales to institutions carrying out research, but the promised land is filled with sales to hospitals.

Feedback Medical Limited has self-certified TexRAD Lung as a Class I Medical Device, in compliance with the requirements of the EU Medical Device Directive, meaning TexRAD Lung is a Medical Device CE marked for use in the EU. This will enable Feedback to lend numerical support to the very skilled, interpretative work carried out by radiologists.

Meanwhile, a tie-up with a company in Poland called Future Processing provides Feedback with the coding know-how to develop a wider product suite.

Demand for product

Sales of the current product, though modest, reveal there is demand from a very specialist audience in the research sphere.

It means the technology is being cited in the literature by some of the leading centres for cancer research – providing a great endorsement of the TexRAD from key opinion leaders.

In fact, the technology is also starting to make an impression with businesses operating in the field.

The stock advanced 0.3p to 2.10p.

---Adds background---

 

]]>
Wed, 15 Aug 2018 07:28:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/202923/feedback-lands-first-contract-from-its-tie-up-with-imaging-giant-ge-healthcare-202923.html
<![CDATA[RNS press release - First GE Healthcare order for TexRAD® ]]> https://www.proactiveinvestors.co.uk/companies/rns/353/LSE20180815070004_13755666/ Wed, 15 Aug 2018 07:00:04 +0100 https://www.proactiveinvestors.co.uk/companies/rns/353/LSE20180815070004_13755666/ <![CDATA[RNS press release - Director/PDMR Shareholding ]]> https://www.proactiveinvestors.co.uk/companies/rns/353/LSE20180801131951_13740022/ Wed, 01 Aug 2018 13:19:51 +0100 https://www.proactiveinvestors.co.uk/companies/rns/353/LSE20180801131951_13740022/ <![CDATA[News - Feedback boss David Crabb leaves with immediate effect ]]> https://www.proactiveinvestors.co.uk/companies/news/201207/feedback-boss-david-crabb-leaves-with-immediate-effect-201207.html David Crabb, the chief executive of Feedback plc (LON:FDBK), has left the specialist medical imaging group with immediate effect.

Crabb only joined in February but is stepping down “in order to devote more time to his other business interests”.

READ: New Feedback boss sets out his stall

The search for a new boss is underway and Dr Alastair Riddell will assume the role of executive chairman in the meantime.

“On behalf of the board I would like to acknowledge and thank David for his contribution to Feedback,” said Riddell.

“We wish him well with his future endeavours.”

Feedback, which owns a smart piece of software that analyses medical images to reveal features that are not always evident to the human eye, will make a further announcement in due course.

]]>
Fri, 20 Jul 2018 07:27:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/201207/feedback-boss-david-crabb-leaves-with-immediate-effect-201207.html
<![CDATA[RNS press release - Directorate Change ]]> https://www.proactiveinvestors.co.uk/companies/rns/353/LSE20180720070003_13725037/ Fri, 20 Jul 2018 07:00:03 +0100 https://www.proactiveinvestors.co.uk/companies/rns/353/LSE20180720070003_13725037/ <![CDATA[RNS press release - Joint broker update ]]> https://www.proactiveinvestors.co.uk/companies/rns/353/LSE20180706070003_13707841/ Fri, 06 Jul 2018 07:00:03 +0100 https://www.proactiveinvestors.co.uk/companies/rns/353/LSE20180706070003_13707841/ <![CDATA[RNS press release - Director/PDMR Shareholding ]]> https://www.proactiveinvestors.co.uk/companies/rns/353/LSE20180629152055_13700019/ Fri, 29 Jun 2018 15:20:55 +0100 https://www.proactiveinvestors.co.uk/companies/rns/353/LSE20180629152055_13700019/